Researchers at the University of Tsukuba conducted a three-year observational study (January 2019–December 2021) using a ...
The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
Emerging treatments for advanced cholangiocarcinoma: Addressing the knowledge gap. Background: HCC is a leading cause of cancer-related deaths worldwide. LEN is now a first-line treatment option for ...
Sodium-glucose cotransporter 2 (SGLT2) inhibition seems to reduce the progression of nonsevere aortic stenosis over 5 years, with a larger treatment effect seen in those who take the drugs the longest ...